Skip to main content

Advertisement

SpringerLink
Log in

Current Trends in the Management of Malignant Peritoneal Mesothelioma

  • Gastrointestinal Oncology
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

Historically, malignant peritoneal mesothelioma (MPM) has been considered an aggressive and lethal neoplasm. However, contemporary series have demonstrated improved outcomes following a combination of cytoreductive surgery and intraperitoneal chemotherapy. We sought to assess the trends in management and survival of patients with MPM in the United States.

Methods

The Surveillance, Epidemiology, and End Results database was used to identify all patients diagnosed with malignant peritoneal mesothelioma from 1973 to 2010. Overall survival (OS) was studied with Kaplan–Meier curves and Cox regression analyses.

Results

We identified 1,591 patients with MPM. Median age at diagnosis was 64 years (IQR 53–74 years) with the majority of patients presenting with metastatic disease (n = 962, 60.5 %). A total of 980 patients (61.6 %) did not receive surgical therapy. Receipt of radical cytoreduction for patients with metastatic MPM demonstrated a significant improvement in OS compared with patients not receiving surgery (20 vs. 4 months, p < 0.01). A temporal increase was observed in OS for patients receiving surgery (1991–1995: 15 vs. 2006–2010: 38 months, p = 0.1). In multivariate models, limited (HR 0.55; 95 % CI 0.48–0.63; p < 0.01) and radical (HR 0.66; 95 % CI 0.54–0.80; p < 0.01) surgery were independently associated with improved survival.

Conclusions

In the current era, approximately three of every five patients do not receive surgery when diagnosed with MPM, although a significant survival benefit is noted in select patients. The opportunity to improve patient survival with surgical therapy is lost in a significant number of MPM patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Price B, Ware A. Time trend of mesothelioma incidence in the United States and projection of future cases: an update based on SEER data for 1973 through 2005. Crit Rev Toxicol. 2009;39:576–88.

    Article  PubMed  Google Scholar 

  2. Boffetta P. Epidemiology of peritoneal mesothelioma: a review. Ann Oncol. 2007;18:985–90.

    Article  PubMed  CAS  Google Scholar 

  3. Bridda A, Padoan I, Mencarelli R, Frego M. Peritoneal mesothelioma: a review. MedGenMed. 2007;9:32.

    PubMed  PubMed Central  Google Scholar 

  4. Yan TD, Deraco M, Elias D, Glehen O, Levine EA, Moran BJ, et al. A novel tumor-node-metastasis (TNM) staging system of diffuse malignant peritoneal mesothelioma using outcome analysis of a multi-institutional database*. Cancer. 2011;117:1855–63.

    Article  PubMed  Google Scholar 

  5. Yan TD, Welch L, Black D, Sugarbaker PH. A systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for diffuse malignancy peritoneal mesothelioma. Ann Oncol. 2007;18:827–34.

    Article  PubMed  CAS  Google Scholar 

  6. Chua TC, Yan TD, Morris DL. Outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma: the Australian experience. J Surg Oncol. 2009;99:109–13.

    Article  PubMed  Google Scholar 

  7. Moertel CG. Peritoneal mesothelioma. Gastroenterology. 1972;63:346–50.

    PubMed  CAS  Google Scholar 

  8. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21:2636–44.

    Article  PubMed  CAS  Google Scholar 

  9. Jänne PA, Simon GR, Langer CJ, Taub RN, Dowlati A, Fidias P, et al. Phase II trial of pemetrexed and gemcitabine in chemotherapy-naive malignant pleural mesothelioma. J Clin Oncol. 2008;26:1465–71.

    Article  PubMed  Google Scholar 

  10. Jänne PA, Wozniak AJ, Belani CP, Keohan ML, Ross HJ, Polikoff JA, et al. Open-label study of pemetrexed alone or in combination with cisplatin for the treatment of patients with peritoneal mesothelioma: outcomes of an expanded access program. Clin Lung Cancer. 2005;7:40–6.

    Article  PubMed  Google Scholar 

  11. Lainakis G, Zagouri F, Kastritis E, Sergentanis TN, Bozas G, Dimopoulos MA, et al. Systemic chemotherapy with pemetrexed and cisplatin for malignant peritoneal mesothelioma: a single institution experience. Tumori. 2011;97:25–9.

    PubMed  CAS  Google Scholar 

  12. Carteni G, Manegold C, Garcia GM, Siena S, Zielinski CC, Amadori D, et al. Malignant peritoneal mesothelioma—Results from the International Expanded Access Program using pemetrexed alone or in combination with a platinum agent. Lung Cancer. 2009;64:211–8.

    Article  PubMed  CAS  Google Scholar 

  13. Magge D, Zenati MS, Austin F, Mavanur A, Sathaiah M, Ramalingam L, et al. Malignant peritoneal mesothelioma: prognostic factors and oncologic outcome analysis. Ann Surg Oncol. 2014;21:1159–65.

    Article  PubMed  Google Scholar 

  14. Passot G, Cotte E, Brigand C, Beaujard AC, Isaac S, Gilly FN, et al. [Peritoneal mesothelioma: treatment with cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy]. J Chir (Paris). 2008;145:447–53.

    Article  PubMed  CAS  Google Scholar 

  15. Yan TD, Brun EA, Cerruto CA, Haveric N, Chang D, Sugarbaker PH. Prognostic indicators for patients undergoing cytoreductive surgery and perioperative intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma. Ann Surg Oncol. 2007;14:41–9.

    Article  PubMed  Google Scholar 

  16. Baratti D, Kusamura S, Deraco M. Diffuse malignant peritoneal mesothelioma: systematic review of clinical management and biological research. J Surg Oncol. 2011;103:822–31.

    Article  PubMed  Google Scholar 

  17. Langer CJ, Rosenblum N, Hogan M, Nash S, Bagchi P, LaCreta FP, et al. Intraperitoneal cisplatin and etoposide in peritoneal mesothelioma: favorable outcome with a multimodality approach. Cancer Chemother Pharmacol. 1993;32:204–8.

    Article  PubMed  CAS  Google Scholar 

  18. Lederman GS, Recht A, Herman T, Osteen R, Corson J, Antman KH. Long-term survival in peritoneal mesothelioma. The role of radiotherapy and combined modality treatment. Cancer. 1987;59:1882–6.

    Article  PubMed  CAS  Google Scholar 

  19. Rodríguez D, Cheung MC, Housri N, Koniaris LG. Malignant abdominal mesothelioma: defining the role of surgery. J Surg Oncol. 2009;99:51–7.

    Article  PubMed  Google Scholar 

  20. Loggie BW, Fleming RA, McQuellon RP, Russell GB, Geisinger KR, Levine EA. Prospective trial for the treatment of malignant peritoneal mesothelioma. Am Surg. 2001;67:999–1003.

    PubMed  CAS  Google Scholar 

  21. Sebbag G, Yan H, Shmookler BM, Chang D, Sugarbaker PH. Results of treatment of 33 patients with peritoneal mesothelioma. Br J Surg. 2000;87:1587–93.

    Article  PubMed  CAS  Google Scholar 

  22. Feldman AL, Libutti SK, Pingpank JF, Bartlett DL, Beresnev TH, Mavroukakis SM, et al. Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. J Clin Oncol. 2003;21:4560–7.

    Article  PubMed  CAS  Google Scholar 

  23. Elias D, Bedard V, Bouzid T, Duvillard P, Kohneh-Sharhi N, Raynard B, et al. Malignant peritoneal mesothelioma: treatment with maximal cytoreductive surgery plus intraperitoneal chemotherapy. Gastroenterol Clin Biol. 2007;31:784–8.

    Article  PubMed  Google Scholar 

  24. Yan TD, Deraco M, Baratti D, Kusamura S, Elias D, Glehen O, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol. 2009;27:6237–42.

    Article  PubMed  Google Scholar 

  25. Mirarabshahii P, Pillai K, Chua TC, Pourgholami MH, Morris DL. Diffuse malignant peritoneal mesothelioma–an update on treatment. Cancer Treat Rev. 2012;38:605–12.

    Article  PubMed  Google Scholar 

  26. Le DT, Deavers M, Hunt K, Malpica A, Verschraegen CF. Cisplatin and irinotecan (CPT-11) for peritoneal mesothelioma. Cancer Invest. 2003;21:682–9.

    Article  PubMed  CAS  Google Scholar 

  27. Simon GR, Verschraegen CF, Jänne PA, Langer CJ, Dowlati A, Gadgeel SM, et al. Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: final report of a phase II trial. J Clin Oncol. 2008;26:3567–72.

    Article  PubMed  CAS  Google Scholar 

Download references

Disclosures

No relevant financial disclosures.

Author information

Authors and Affiliations

  1. Division of Surgical Oncology, Department of Surgery, Medical College of Wisconsin, Milwaukee, WI, USA

    John T. Miura MD, Fabian M. Johnston MD, MHS, T. Clark Gamblin MD, MS & Kiran K. Turaga MD, MPH

Authors
  1. John T. Miura MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Fabian M. Johnston MD, MHS
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. T. Clark Gamblin MD, MS
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kiran K. Turaga MD, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kiran K. Turaga MD, MPH.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Miura, J.T., Johnston, F.M., Gamblin, T.C. et al. Current Trends in the Management of Malignant Peritoneal Mesothelioma. Ann Surg Oncol 21, 3947–3953 (2014). https://doi.org/10.1245/s10434-014-3803-6

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-014-3803-6

Keywords

Search

Navigation